Herantis Pharma Oyj Total Liabilities
Herantis Pharma Oyj total liabilities. Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has total liabilities worth €3.36 Million EUR (≈ $3.93 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Herantis Pharma Oyj liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Herantis Pharma Oyj (2011–2024)
Total liabilities of Herantis Pharma Oyj from 2011 to 2024. This chart illustrates how Herantis Pharma Oyj's total liabilities have evolved over time, based on quarterly financial data. Explore Herantis Pharma Oyj strategic investment ratio to see how much of total assets are deployed in long-term investments.
Herantis Pharma Oyj Competitors by Total Liabilities
The table below lists competitors of Herantis Pharma Oyj ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
USA | $68.87 Million |
|
DNA Biomed Solns
TA:DNA
|
Israel | ILA1.77 Million |
|
Hana Must SPAC 2
KQ:208370
|
Korea | ₩6.87 Billion |
|
Logistea A
ST:LOGI-A
|
Sweden | Skr11.09 Billion |
|
Samkee Automotive Co. Ltd
KQ:122350
|
Korea | ₩569.21 Billion |
|
Pacific Orient Bhd
KLSE:6009
|
Malaysia | RM784.00 Million |
|
Coventry Group Ltd
AU:CYG
|
Australia | AU$205.48 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Herantis Pharma Oyj's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HRTIS current and non-current assets.
Liquidity & Leverage Metrics
Herantis Pharma Oyj Total Liabilities Ratios Explained
Herantis Pharma Oyj total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.71 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.92 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Herantis Pharma Oyj's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Herantis Pharma Oyj (2011–2024)
The table below shows the annual total liabilities of Herantis Pharma Oyj from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.81 Million ≈ $3.29 Million |
+39.36% |
| 2023-12-31 | €2.02 Million ≈ $2.36 Million |
-67.91% |
| 2022-12-31 | €6.29 Million ≈ $7.36 Million |
-1.12% |
| 2021-12-31 | €6.36 Million ≈ $7.44 Million |
-27.95% |
| 2020-12-31 | €8.83 Million ≈ $10.33 Million |
-4.19% |
| 2019-12-31 | €9.22 Million ≈ $10.78 Million |
+27.40% |
| 2018-12-31 | €7.24 Million ≈ $8.46 Million |
-3.28% |
| 2017-12-31 | €7.48 Million ≈ $8.75 Million |
-13.31% |
| 2016-12-31 | €8.63 Million ≈ $10.09 Million |
+6.69% |
| 2015-12-31 | €8.09 Million ≈ $9.46 Million |
+4.05% |
| 2014-12-31 | €7.77 Million ≈ $9.09 Million |
+208.39% |
| 2013-12-31 | €2.52 Million ≈ $2.95 Million |
+13.82% |
| 2012-12-31 | €2.21 Million ≈ $2.59 Million |
+15.35% |
| 2011-12-31 | €1.92 Million ≈ $2.24 Million |
-- |
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more